Provided by Tiger Trade Technology Pte. Ltd.

MaxCyte Inc

1.29
+0.07005.74%
Post-market: 1.300.0100+0.78%16:11 EDT
Volume:774.86K
Turnover:984.70K
Market Cap:133.14M
PE:-3.86
High:1.32
Open:1.19
Low:1.19
Close:1.22
52wk High:1.87
52wk Low:0.6434
Shares:103.21M
Float Shares:92.68M
Volume Ratio:1.80
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3338
EPS(LYR):-0.4200
ROE:-20.39%
ROA:-10.64%
PB:0.84
PE(LYR):-3.07

Loading ...

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

THOMSON REUTERS
·
May 13

MaxCyte Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
May 09

MaxCyte announces annual shareholder meeting

Reuters
·
Apr 30

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

GlobeNewswire
·
Apr 30

Barinthus Biotherapeutics appoints Douglas Swirsky as CFO effective May 1

Reuters
·
Apr 23

MaxCyte CFO Parmeet Ahuja files initial beneficial ownership statement (Form 3)

Reuters
·
Apr 11

MaxCyte grants CFO Parmeet Ahuja 375,000 stock options under inducement plan

Reuters
·
Apr 01

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 01

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)

TIPRANKS
·
Mar 30

MaxCyte Appoints New Chief Financial Officer Ahuja

TIPRANKS
·
Mar 28

MaxCyte appoints Parmeet Ahuja CFO effective March 30, 2026; Douglas Swirsky transitions from the role

Reuters
·
Mar 28

MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access

TIPRANKS
·
Mar 27

MaxCyte Is Maintained at Buy by Craig-Hallum

Dow Jones
·
Mar 26

MaxCyte price target lowered to $5 from $7 at Craig-Hallum

TIPRANKS
·
Mar 25

MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook

TIPRANKS
·
Mar 25

MaxCyte Inc: Q4 EPS $-0.09 - SEC Filing

THOMSON REUTERS
·
Mar 25

MaxCyte reports Q4 EPS (9c), consensus (8c)

TIPRANKS
·
Mar 25

MaxCyte Q4 2025 revenue fell 16% to USD 7.3 million as net loss narrowed to USD 10 million

Reuters
·
Mar 25

MaxCyte Q4 EPS $(0.09), Inline, Sales $7.300M Miss $9.398M Estimate

Benzinga Earnings
·
Mar 25

Press Release: MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Dow Jones
·
Mar 25